BR0008313A - Composições e métodos para ativação não-direcionada de genes endógenos - Google Patents

Composições e métodos para ativação não-direcionada de genes endógenos

Info

Publication number
BR0008313A
BR0008313A BR0008313-5A BR0008313A BR0008313A BR 0008313 A BR0008313 A BR 0008313A BR 0008313 A BR0008313 A BR 0008313A BR 0008313 A BR0008313 A BR 0008313A
Authority
BR
Brazil
Prior art keywords
gene
genes
methods
expression
directed
Prior art date
Application number
BR0008313-5A
Other languages
English (en)
Inventor
John J Harrington
Bruce Sherf
Stephen Rundlett
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/276,820 external-priority patent/US6897066B1/en
Application filed by Athersys Inc filed Critical Athersys Inc
Publication of BR0008313A publication Critical patent/BR0008313A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA ATIVAçãO NãO-DIRECIONADA DE GENES ENDóGENOS". A presente invenção é dirigida de forma geral à ativação da expressão de gene ou à produção de superexpressão de um gene por métodos de recombinação in situ. A invenção também é direcionada de forma geral aos métodos para a expressão de um gene endógeno em uma célula em níveis maiores do que aqueles normalmente encontrados na célula. Em uma modalidade da invenção, a expressão de um gene endógeno é ativada ou aumentada após integração na célula, por recombinação não-homóloga ou ilegítima, de uma seq³ência reguladora que ativa a expressão do gene. Em outra modalidade, a expressão do gene endógeno pode ainda ser aumentada por co-integração de um ou mais marcadores amplificáveis, e selecionando-se cópias aumentadas de um ou mais marcadores amplificáveis localizados no vetor integrado. Em outra modalidade, a invenção é dirigida à ativação de genes endógenos por integração não direcionada de vetores de ativação não especializados, que são fornecidos pela invenção, no genoma de uma célula hospedeira. A invenção também fornece métodos para a identificação, ativação, isolamento, e/ou expressão de genes não descobertos por métodos atuais uma vez que nenhuma seq³ência alvo é necessária para integração. A invenção também fornece métodos para isolamento de moléculas de ácido nucléico (particularmente moléculas de cDNA) que codificam diversas proteínas, incluindo proteínas transmembrana, e para o isolamento de células que expressam tais proteínas transmembrana, que podem ser proteínas transmembrana heterólogas. A invenção também é dirigida a genes isolados, produtos de gene, moléculas de ácido nucléico, e a composições que compreendem tais genes, produtos de gene e moléculas de ácido nucléico, e a vetores e células hospedeiras que compreendem tais genes e moléculas de ácido nucléico, que podem ser usados em diversas aplicações terapêuticas e diagnósticas. Dessa forma, pela presente invenção, genes endógenos, incluindo aqueles associados com doenças humanas e desenvolvimento, podem ser ativados e isolados sem conhecimento prévio do perfil da seq³ência, estrutura, função, ou expressão dos genes.
BR0008313-5A 1999-02-19 2000-02-22 Composições e métodos para ativação não-direcionada de genes endógenos BR0008313A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25302299A 1999-02-19 1999-02-19
US26381499A 1999-03-08 1999-03-08
US09/276,820 US6897066B1 (en) 1997-09-26 1999-03-26 Compositions and methods for non-targeted activation of endogenous genes
PCT/US2000/004429 WO2000049162A2 (en) 1999-02-19 2000-02-22 Compositions and methods for non-targeted activation of endogenous genes

Publications (1)

Publication Number Publication Date
BR0008313A true BR0008313A (pt) 2003-09-23

Family

ID=27400625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008313-5A BR0008313A (pt) 1999-02-19 2000-02-22 Composições e métodos para ativação não-direcionada de genes endógenos

Country Status (8)

Country Link
EP (1) EP1155131B1 (pt)
JP (1) JP2004501601A (pt)
CN (1) CN1384881A (pt)
AU (1) AU3003700A (pt)
BR (1) BR0008313A (pt)
CA (1) CA2364267A1 (pt)
IL (1) IL144960A0 (pt)
WO (1) WO2000049162A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
CA2304642C (en) * 1997-09-26 2014-11-18 Athersys, Inc. Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
CA2788000C (en) 2003-05-01 2016-03-15 Medgenics Inc. Apparatus for harvesting a dermal micro-organ
EP1662005A1 (en) * 2004-11-26 2006-05-31 FrankGen Biotechnologie AG Enhancer-containing gene trap vectors for random and targeted gene trapping
JP4856177B2 (ja) * 2005-06-24 2012-01-18 ユニジーン・ラボラトリーズ・インコーポレーテッド アミド化生成物の調製に有用な酵素を発現させるための細胞株
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
JP2016514477A (ja) * 2013-03-30 2016-05-23 ウーシャ バイオテック リミテッド 哺乳動物細胞内で生物活性タンパク質を発現させるための方法および構築物
EP3919621A1 (en) * 2014-06-23 2021-12-08 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
CN109312293B (zh) * 2016-04-30 2022-09-16 百进生物科技公司 用于进行磁浮分离的组合物和方法
CN111593037B (zh) * 2020-06-15 2021-02-09 南通大学 一种高效的爬行动物来源的凝血酶及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034135T3 (de) * 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
ATE231920T1 (de) * 1992-03-11 2003-02-15 Dana Farber Cancer Inst Inc Methode um mrna zu klonieren
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
JPH09173100A (ja) * 1995-10-27 1997-07-08 Sapporo Breweries Ltd ホップ潜在ウイルスの遺伝子及び該ウイルスの検出方法
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
EP0885307A1 (en) * 1996-02-09 1998-12-23 Vereniging Het Nederlands Kanker Instituut Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
WO1998012337A1 (en) * 1996-09-23 1998-03-26 Chiron Corporation Random and targeted promoter integration for gene analysis
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
WO1998040510A1 (en) * 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
AU9160398A (en) * 1997-07-22 1999-02-16 Novimmune Sa Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
EP1003899A1 (en) * 1997-08-12 2000-05-31 Het Nederlands Kanker Instituut Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
CA2304642C (en) * 1997-09-26 2014-11-18 Athersys, Inc. Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
ATE400660T1 (de) * 1998-03-27 2008-07-15 Lexicon Pharmaceuticals Inc Vektoren für genmutagenese und genentdeckung
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery

Also Published As

Publication number Publication date
AU3003700A (en) 2000-09-04
JP2004501601A (ja) 2004-01-22
CN1384881A (zh) 2002-12-11
WO2000049162A3 (en) 2000-12-28
WO2000049162A8 (en) 2001-03-01
EP1155131B1 (en) 2008-07-23
WO2000049162A2 (en) 2000-08-24
CA2364267A1 (en) 2000-08-24
IL144960A0 (en) 2002-06-30
EP1155131A2 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
BR9812540A (pt) Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular
Kweon et al. An adversarial DNA N6-methyladenine-sensor network preserves polycomb silencing
BR0008313A (pt) Composições e métodos para ativação não-direcionada de genes endógenos
Larsen et al. Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks
Erceg et al. Dual functionality of cis-regulatory elements as developmental enhancers and Polycomb response elements
Hou et al. SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression
Bernstein et al. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts
Wang et al. Genetic analysis of the SR protein ASF/SF2: interchangeability of RS domains and negative control of splicing
Maniar et al. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level
Wang et al. Z-DNA-forming sequences generate large-scale deletions in mammalian cells
Omori et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio-and chemosensitivity in a human lung carcinoma cell line
Estève et al. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters
Ohmori et al. Interleukin-4/STAT6 represses STAT1 and NF-κB-dependent transcription through distinct mechanisms
Liu et al. Genetic analysis of Down syndrome-associated heart defects in mice
Do Kim et al. Identification of clustered YY1 binding sites in imprinting control regions
Yu et al. Mitochondrial DNA hypomethylation is a biomarker associated with induced senescence in human fetal heart mesenchymal stem cells
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
Hsu et al. Two major forms of DNA (cytosine-5) methyltransferase in human somatic tissues
Prabhakar et al. Focus: drug development: exploiting long noncoding RNAs as pharmacological targets to modulate epigenetic diseases
EP3307888A1 (en) New crispr assays
Wilkin et al. H19 sense and antisense transgenes modify insulin‐like growth factor‐II mRNA levels
Du et al. The KCNQ1OT1 promoter, a key regulator of genomic imprinting in human chromosome 11p15. 5
Sjeklocha et al. β‐globin matrix attachment region improves stable genomic expression of the Sleeping beauty transposon
Botta et al. Targeting and silencing of rhodopsin by ectopic expression of the transcription factor KLF15
Tatsumi et al. 2′, 5′-oligoadenylate synthetase gene in chicken: gene structure, distribution of alleles and their expression

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.